Bristol-Myers Squibb Company

BMY · CIK 0000014272

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$48.19B0.2%

FY2025

Net income (FY)

$7.05B178.8%

FY2025

Free cash flow (FY)

$12.85B7.9%

FY2025

Diluted EPS (FY)

$3.46178.5%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 3.1× since FY2007 · net margin 13.9% → 14.6%

MarginsNet marginFCF margin

FY2025: net 14.6% · free cash flow 26.7% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $14.16B operating cash − $1.31B capex = $12.85B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 43% (FY2008) → 38% (FY2025) · on assets 7.8%

Balance sheetLiabilitiesEquity

FY2025: $90.04B assets · $71.53B liabilities · $18.47B equity

The receipts

Bristol-Myers Squibb Company

BMY · CIK 0000014272

19 fiscal years · 68 SEC filings · every number carries its receipt

Revenue (FY)

$48.19B0.2%

FY2025

Net income (FY)

$7.05B178.8%

FY2025

Free cash flow (FY)

$12.85B7.9%

FY2025

Diluted EPS (FY)

$3.46178.5%

FY2025

The story, charted

The shape of the business

FY2007–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 3.1× since FY2007 · net margin 13.9% → 14.6%

MarginsNet marginFCF margin

FY2025: net 14.6% · free cash flow 26.7% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $14.16B operating cash − $1.31B capex = $12.85B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 43% (FY2008) → 38% (FY2025) · on assets 7.8%

Balance sheetLiabilitiesEquity

FY2025: $90.04B assets · $71.53B liabilities · $18.47B equity

The receipts